Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality
- PMID: 9002492
Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality
Abstract
Objective: To determine the excess length of stay, extra costs, and mortality attributable to adverse drug events (ADEs) in hospitalized patients.
Design: Matched case-control study.
Setting: The LDS Hospital, a tertiary care health care institution.
Patients: All patients admitted to LDS Hospital from January 1, 1990, to December 31, 1993, were eligible. Cases were defined as patients with ADEs that occurred during hospitalization; controls were selected according to matching variables in a stepwise fashion.
Methods: Controls were matched to cases on primary discharge diagnosis related group (DRG), age, sex, acuity, and year of admission; varying numbers of controls were matched to each case. Matching was successful for 71% of the cases, leading to 1580 cases and 20,197 controls.
Main outcome measures: Crude and attributable mortality, crude and attributable length of stay, and cost of hospitalization.
Results: ADEs complicated 2.43 per 100 admissions to the LDS Hospital during the study period. The crude mortality rates for the cases and matched controls were 3.5% and 1.05%, respectively (P<.001). The mean length of hospital stay significantly differed between the cases and matched controls (7.69 vs 4.46 days; P<.001) as did the mean cost of hospitalization ($10,010 vs $5355; P<.001). The extra length of hospital stay attributable to an ADE was 1.74 days (P<.001). The excess cost of hospitalization attributable to an ADE was $2013 (P<.001). A linear regression analysis for length of stay and cost controlling for all matching variables revealed that the occurrence of an ADE was associated with increased length of stay of 1.91 days and an increased cost of $2262 (P<.001). In a similar logistic regression analysis for mortality, the increased risk of death among patients experiencing an ADE was 1.88 (95% confidence interval, 1.54-2.22; P<.001).
Conclusion: The attributable lengths of stay and costs of hospitalization for ADEs are substantial. An ADE is associated with a significantly prolonged length of stay, increased economic burden, and an almost 2-fold increased risk of death.
Comment in
-
Putting adverse drug events into perspective.JAMA. 1997 Jan 22-29;277(4):341-2. JAMA. 1997. PMID: 9002498 No abstract available.
-
Adverse drug events in hospitalized patients.JAMA. 1997 May 7;277(17):1351; author reply 1353-4. doi: 10.1001/jama.277.17.1351c. JAMA. 1997. PMID: 9134930 No abstract available.
-
Adverse drug events in hospitalized patients.JAMA. 1997 May 7;277(17):1351; author reply 1353-4. doi: 10.1001/jama.277.17.1351b. JAMA. 1997. PMID: 9134931 No abstract available.
-
Adverse drug events in hospitalized patients.JAMA. 1997 May 7;277(17):1351-2; author reply 1353-4. JAMA. 1997. PMID: 9134932 No abstract available.
-
Adverse drug events in hospitalized patients.JAMA. 1997 May 7;277(17):1352-3; author reply 1353-4. JAMA. 1997. PMID: 9134933 No abstract available.
Similar articles
-
Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality.JAMA. 1994 May 25;271(20):1598-601. doi: 10.1001/jama.271.20.1598. JAMA. 1994. PMID: 8182812
-
The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.JAMA. 1997 Jan 22-29;277(4):307-11. JAMA. 1997. PMID: 9002493
-
Healthcare-associated Staphylococcus aureus bloodstream infection: length of stay, attributable mortality, and additional direct costs.Braz J Infect Dis. 2012 Nov-Dec;16(6):503-9. doi: 10.1016/j.bjid.2012.10.001. Epub 2012 Nov 15. Braz J Infect Dis. 2012. PMID: 23158266
-
Excess length of hospital stay due to healthcare acquired infections: methodologies evaluation.Ann Ig. 2019 Sep-Oct;31(5):507-516. doi: 10.7416/ai.2019.2311. Ann Ig. 2019. PMID: 31304530 Review.
-
Gender and hospital resource use. Unexpected differences.Eval Health Prof. 1993 Jun;16(2):177-89. doi: 10.1177/016327879301600203. Eval Health Prof. 1993. PMID: 10125775 Review.
Cited by
-
Improving adverse drug event reporting by healthcare professionals.Cochrane Database Syst Rev. 2024 Oct 29;10(10):CD012594. doi: 10.1002/14651858.CD012594.pub2. Cochrane Database Syst Rev. 2024. PMID: 39470185 Free PMC article. Review.
-
Evaluating the Economic Impact of the PedAMINES App in Reducing Medication Errors in Pediatric Emergency Care: Cost-Effectiveness Analysis.J Med Internet Res. 2024 Oct 25;26:e52077. doi: 10.2196/52077. J Med Internet Res. 2024. PMID: 39454199
-
Improvement in Adverse Drug Reaction (ADR) Knowledge: A Pre- and Post-video Intervention Study Among Doctors.Cureus. 2024 Aug 23;16(8):e67622. doi: 10.7759/cureus.67622. eCollection 2024 Aug. Cureus. 2024. PMID: 39314617 Free PMC article.
-
Adverse Drug Reactions Related with Antibiotic Medicines in Malawi: A Retrospective Analysis of Prevalence and Associated Factors.Drug Healthc Patient Saf. 2024 Jul 23;16:89-101. doi: 10.2147/DHPS.S468966. eCollection 2024. Drug Healthc Patient Saf. 2024. PMID: 39070704 Free PMC article.
-
Causality, Severity, Preventability and Predictability Assessments Scales for Adverse Drug Reactions: A Review.Cureus. 2024 May 9;16(5):e59975. doi: 10.7759/cureus.59975. eCollection 2024 May. Cureus. 2024. PMID: 38854273 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
